Objective: This study investigated nucleoside transport activity and transporter polypeptide expression in erythrocytes from beta-thalassemia major patients to determine if inhibition of transport activity is a sensitive indicator of oxidative membrane damage.
Materials And Methods: Blood samples were obtained from 54 patients, diagnosed as having beta-thalassemia major prior to therapeutic transfusion, and 20 normal subjects. Uptake of (3)H-uridine into washed erythrocytes was measured at room temperature using short incubation periods (5 s) and a rapid inhibitor oil stop protocol. Erythrocyte membranes were analyzed by SDS-PAGE and nucleoside (hENT1) and glucose (GLUT-1) transporter polypeptides quantitated on immunoblots.
Results: Uridine uptake was significantly lower in beta-thalassemic cells than in normal erythrocytes (20.03 +/- 1.08 pmol/10(8) cells/ 5 s, mean +/- SEM, n = 31, vs. 31.15 +/- 1.21 pmol/10(8) cells/5 s, n = 20; p < 0.0001). Expression of hENT1 was significantly lower in beta-thalassemic cells (23.90 +/- 1.01 arbitrary units, n = 54) than in controls (101.20 +/- 2.43 arbitrary units, n = 20; p < 0.001) but expression of GLUT-1 was not changed appreciably (101.80 +/- 2.43 arbitrary units, n = 54, for thalassemic cells; 102.60 +/- 3.02 arbitrary units, n = 20, for control cells; p = 0.87).
Conclusions: Erythrocytes from beta-thalassemia major patients showed decreased uridine transport which was associated with decreased nucleoside transporter expression. The process(es) mediating a selective decrease in hENT1 polypeptides in beta-thalassemia major was/were not determined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000204347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A scoping review on the obstacles faced by beta thalassemia major patients in Pakistan- Matter of policy investment.
AIMS Public Health
November 2024
Community health science, Aga Khan University Karachi, Pakistan.
Beta-thalassemia major (β-TM) is a genetic disorder, prevalent especially in the Mediterranean region, Southeast Asia, and the Indian subcontinent. With improvements in management over the years, β-TM has transitioned from a fatal childhood disease to a chronic condition. However, in Pakistan, there is still a lack of a comprehensive national policy and strategic plan, which has resulted in a growing number of β-TM patients, placing a substantial burden on individuals and the national healthcare system.
View Article and Find Full Text PDFA β-Thalassemia Cell Biobank: Updates, Further Validation in Genetic and Therapeutic Research and Opportunities During (and After) the COVID-19 Pandemic.
J Clin Med
January 2025
Department of Life Sciences and Biotechnology, Ferrara University, 44121 Ferrara, Italy.
: Cellular biobanks are of great interest for performing studies finalized in the development of personalized approaches for genetic diseases, including β-thalassemia and sickle cell disease (SCD), important diseases affecting the hematopoietic system. These inherited genetic diseases are characterized by a global distribution and the need for intensive health care. The aim of this report is to present an update on the composition of a cellular Thal-Biobank, to describe its utilization since 2016, to present data on its application in studies on fetal hemoglobin induction and on gene editing, and to discuss its employment as a "unique tool" during and after the COVID-19 pandemic.
View Article and Find Full Text PDFGene therapy for β-thalassemia: current and future options.
Trends Mol Med
January 2025
Université Paris Cité, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR 1163, 75015, Paris, France.
Beta-thalassemia is a severe, hereditary blood disorder characterized by anemia, transfusion dependence, reduced life expectancy, and poor quality of life. Allogeneic transplantation of hematopoietic stem cells (HSCs) is the only curative treatment for transfusion-dependent β-thalassemia, but a lack of compatible donors prevents the use of this approach for most patients. Over the past 20 years, the rise of gene therapy and the development of lentiviral vectors and genome-editing tools has extended curative options to a broader range of patients.
View Article and Find Full Text PDFIdentification of a β-Globin Gene Mutation with the Genotype β-28(A > G), IVS-I-5(G > A)/βCD 71/72(+A) Using Third-Generation Sequencing.
Hemoglobin
January 2025
Precision Medical Lab Center, People's Hospital of Yangjiang, Yangjiang, Guangdong, People's Republic of China.
This study presents the hematological and genetic analysis of a child with severe β-thalassemia harboring triple heterozygous mutations. The child, diagnosed with anemia at the age of 1 year, became transfusion-dependent and maintained a hemoglobin level of 72.00-84.
View Article and Find Full Text PDFPrevalence and Spectrum of β-Thalassemia Mutations in Baghdad, Iraq: Data from the Premarital Screening Program.
Hemoglobin
January 2025
Department of Pathology, School of Medicine, University of Duhok, Duhok, Iraq.
The knowledge of the prevalence and molecular basis of β-hemoglobinopathies constitutes an important prerequisite for an effective prevention program. To address this issue in Iraq's capital, Baghdad, a total of 12526 individuals (6263 couples) attending three main Premarital Screening centers were enrolled. Individuals were labeled as β-hemoglobin disorders based on full blood counts and high-performance liquid chromatography.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!